Left Atrial Appendage Closure Devices Market Size, Share & Industry Analysis, By Product Type (Transcatheter LAA Occlusion Devices, Surgical/Epicardial LAA Exclusion Devices, LAA Ligation Systems, and Others), By Atrial Fibrillation Type (Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Long-Standing Persistent, and Others), By End-user (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast, 2026-2034

The global left atrial appendage closure devices market size was valued at USD 2.55 billion in 2025. The market is projected to grow from USD 2.87 billion in 2026 to USD 7.03 billion by 2034, exhibiting a CAGR of 11.8% during the forecast period.

Left atrial appendage closure (LAAC) devices are medical implants used to close or exclude the left atrial appendage, a small pouch extending from the left atrium, to reduce the risk of thrombus formation and thromboembolic stroke in patients with atrial fibrillation. These devices include transcatheter occlusion systems and surgical or epicardial exclusion devices. The global market growth is attributed to the increasing cases of atrial fibrillation worldwide, which is expected to drive the device demand.

Boston Scientific Corporation, Abbott, ATRICURE, INC., LifeTech Scientific Corporation, and Medtronic held the highest market share in 2025 due to a strong focus on product innovation and well-established brand image.

LEFT ATRIAL APPENDAGE CLOSURE DEVICES MARKET TRENDS

Miniaturization and Improved LAA Closure Device Designs to Emerge as a Key Trend

LAAC devices are becoming smaller, easier to implant, and better at sealing the left atrial appendage. Key players are also improving device flexibility, delivery systems, and anatomical fit to support safer and more efficient procedures. Moreover, plug/cage devices are utilized widely. As a result, the dual-seal and disc-and-lobe designs are depicting adoption as physicians are seeking options to accommodate different LAA anatomies.

Furthermore, the surgical LAA closure systems are also evolving toward lower-profile clips and minimally invasive surgical approaches. Additionally, advances in imaging methods are helping simplify implantation workflows, which is expected to support the market growth.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Expanding Eligible AF and Stroke-Risk Population to Fuel Market Growth

Over the past few years, there has been an increase in the number of people living with atrial fibrillation (AF), which is expanding the potential patient base for LAA closure procedures. This risk of atrial fibrillation increases with age and in patients with multiple cardiovascular conditions. For instance, in December, the European Federation of Internal Medicine confirmed that atrial fibrillation (AF) prevalence is projected to double by 2050, driven by the geriatric population, greater awareness, and improved detection.

Further, improved screening and diagnosis in developed countries identify patients for LAA closure procedures. Moreover, the growth in patients with high risk of stroke is also anticipated to increase the product demand worldwide, propelling left atrial appendage closure devices market growth.

MARKET RESTRAINTS

Procedural Complexity and Risk of Complications May Limit Market Expansion

LAA closure procedures require experienced physicians, advanced imaging, and appropriate hospital infrastructure, which smaller healthcare facilities often lack. Moreover, although implantation success rates are high, patients still experience complications such as bleeding, fluid buildup around the heart, device-related blood clots, residual leaks, stroke, or device movement.

• For instance, according to data published by the National Center for Biotechnology Information (NCBI), a September 2024 NCDR Left Atrial Appendage Occlusion Registry analysis of 97,185 WATCHMAN FLX patients reported a 97.5% successful implantation rate. However, at 45 days, major bleeding occurred in 3.1% of patients, pericardial effusion requiring intervention in 0.50%, and device-related thrombus in 0.44%.

Such risks make physicians more cautious when recommending LAA closure, particularly in lower-income countries, which is anticipated to hinder the market growth over the forecast period.

MARKET OPPORTUNITIES

Expanding Use among a Broader AF Patient Population to Create Lucrative Growth Opportunities

In recent years, a broader group of atrial fibrillation patients, who are otherwise eligible for blood-thinning therapy, has been recorded to use LAA closure devices. Also, there has been growing clinical evidence comparing LAA closure with oral anticoagulants. This is expected to increase physician confidence, support wider reimbursement, and encourage referrals from general cardiologists and AF treatment programs.

• For instance, in March 2026, the CHAMPION-AF trial reported that WATCHMAN FLX was comparable with oral anticoagulation for the study’s primary composite endpoint in a broad group of anticoagulation-eligible patients with non-valvular AF.

This is expected to help LAA closure devices to move beyond a relatively narrow patient group and significantly expand the market.

MARKET CHALLENGES

Need for Long-Term Clinical Evidence and Broader Indication Validation to Create Challenges for Market Participants

Although LAA closure is an established stroke-prevention option for selected atrial fibrillation patients, manufacturers still need stronger long-term evidence across broader patient populations. Expanding use beyond patients unsuitable for long-term anticoagulation requires randomized trials, extended follow-up, real-world evidence, and post-market surveillance.

Furthermore, regulators, physicians, and payers require convincing comparative data on long-term safety, stroke prevention, device durability, and overall clinical benefit. Consequently, the need for continuous clinical validation can increase development costs and slow broader indication and reimbursement expansion, challenging the market growth.

Segmentation Analysis

By Product Type

Transcatheter LAA Occlusion Devices Segment Led the Market due to Rising Preference for Minimally Invasive LAA Closure Procedures

Based on product type, the market is segmented into transcatheter LAA occlusion devices, surgical/epicardial LAA exclusion devices, LAA ligation systems, and others. The transcatheter LAA occlusion devices segment is further sub-segmented into plug/cage-type devices, dual-seal/disc-and-lobe devices, and others. On the other hand, the surgical/epicardial LAA exclusion devices segment is sub-classified into clip-based devices and other exclusion devices.

The transcatheter LAA occlusion devices segment accounted for the largest market share in 2025. The segment’s growth is mainly driven by the strong adoption of leading products such as WATCHMAN and Amulet. Further, these devices are widely preferred as they allow LAA closure through a minimally invasive catheter-based procedure without open-heart surgery, which is further anticipated to drive the segment’s growth.

To know how our report can help streamline your business, Speak to Analyst

The surgical/epicardial LAA exclusion devices segment is projected to grow at a CAGR of 11.3% during the forecast period.

By Atrial Fibrillation Type

Paroxysmal Atrial Fibrillation Segment Dominated owing to Large Patient Base and Growing Use of LAA Closure Procedures

By atrial fibrillation type, the market is classified into paroxysmal atrial fibrillation, persistent atrial fibrillation, long-standing persistent, and others.

The paroxysmal atrial fibrillation segment accounted for the largest left atrial appendage closure devices market share in 2025. The segment’s dominance is supported by its large diagnosed patient population and frequent management through electrophysiology and cardiology services. Moreover, several patients undergo catheter ablation or regular rhythm monitoring, which may increase opportunities for clinical evaluation for LAA closure. This is also expected to drive the segment’s growth. Furthermore, the segment is set to hold a market share of 51.6% in 2026.

The persistent atrial fibrillation segment is projected to grow at a CAGR of 13.0% during the forecast period.

By End-user

Hospitals & ASCs Segment Led the Market due to Large Number of Hospitals and Infrastructure Availability to Perform LAA Procedures

On the basis of end-user, the market is segmented into hospitals & ASCs, specialty clinics, and others.

In 2025, the hospitals & ASCs segment dominated the market due to access to specialized personnel, imaging systems, and procedural infrastructure. Moreover, a well-established hospital base in developed countries is anticipated to contribute to the adoption of LAA closure devices. Furthermore, the segment is set to hold a market share of 94.1% in 2026.

The specialty clinics segment is projected to grow at a CAGR of 15.4% during the forecast period.

Left Atrial Appendage Closure Devices Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America accounted for the largest share in 2024, valued at USD 1.68 billion, and maintained its leading position in 2025, with USD 2.13 billion. The region’s dominance is supported by a large base of ASCs and higher penetration of advanced LAA closure devices due to the presence of prominent players. For instance, the Centers for Medicare & Medicaid Services (CMS) in March 2025 stated that there are over 6,500 Medicare-certified ASCs in the U.S.

U.S. Left Atrial Appendage Closure Devices Market

In 2026, the U.S. is anticipated to reach USD 2.33 billion, accounting for approximately 81.0% of the global sales.

Europe

Europe is projected to record a CAGR of 13.0% during the forecast period, the second-highest globally. The market is expected to reach USD 0.22 billion in 2026. The region’s growth is supported by the well-established healthcare infrastructure favoring adoption of LAA closure devices in Germany, the U.K., France, and other countries.

U.K. Left Atrial Appendage Closure Devices Market

The U.K. market is projected to reach USD 0.04 billion in 2026, representing approximately 1.4% of global sales.

Germany Left Atrial Appendage Closure Devices Market

The Germany market is expected to reach USD 0.05 billion in 2026, accounting for approximately 1.7% of global revenues.

Asia Pacific

In 2026, the market in Asia Pacific is projected to reach approximately USD 0.21 billion, making it the third-largest market. The growth is attributed to rising stroke burden and geriatric population, which is increasing evaluation of patients requiring LAA procedures. Moreover, increasing healthcare investments in the region are also expected to further support adoption of LAA devices.

Japan Left Atrial Appendage Closure Devices Market

The Japan market is projected to reach approximately USD 0.05 billion in revenue in 2026, representing nearly 1.8% of the global sales.

China Left Atrial Appendage Closure Devices Market

In 2026, the China market is anticipated to reach USD 0.07 billion, accounting for approximately 2.6% of the global sales.

India Left Atrial Appendage Closure Devices Market

In 2026, the India market is anticipated to reach USD 0.02 billion, accounting for approximately 0.6% of the global sales.

Latin America and the Middle East & Africa

Latin America and the Middle East & Africa are anticipated to witness moderate growth during the forecast period. The Latin America market is estimated to reach approximately USD 0.03 billion in 2026. The market expansion in Latin America is due to growing awareness of left atrial appendage closure device procedures in the region. Moreover, the market growth in the Middle East & Africa is due to prominent players expanding their product reach in emerging countries of the region.

GCC Left Atrial Appendage Closure Devices Market

In 2026, the GCC market is estimated to reach approximately USD 0.01 billion, representing around 0.5% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Major Companies Focus on Strong Footprint and Broad Portfolios to Maintain their Dominant Positions

In 2025, Boston Scientific Corporation, Abbott, ATRICURE, INC., LifeTech Scientific Corporation, and Medtronic held the largest market share. The dominant share of these left atrial appendage closure devices companies is attributed to their strong global footprints and broader portfolios.

Moreover, other prominent players are focusing on strategic initiatives such as partnerships, acquisitions, and mergers to gain a significant market share during the forecast period.

LIST OF KEY LEFT ATRIAL APPENDAGE CLOSURE DEVICES COMPANIES PROFILED

• Boston Scientific Corporation (U.S.)
• Abbott (U.S.)
• ATRICURE, INC. (U.S.)
• LifeTech Scientific Corporation (China)
• Medtronic (Ireland)
• MicroPort Scientific Corporation (China)
• Shanghai Push Medical Devices Co., Ltd. (China)
• Guangdong Pulse Medical Technology Co., Ltd. (China)
• Hangzhou Valued Medtech Co., Ltd. (China)
• Nanjing YDB Medical Technology Co., Ltd. (China)

KEY INDUSTRY DEVELOPMENTS

• August 2026: Abbott’s Amulet 360 received CE Mark in Europe as Abbott’s next-generation LAA occlusion platform.
• May 2026: Genesee BioMedical received FDA 510(k) clearance for the ATLAAS epicardial LAA exclusion system.
• July 2025: Boston Scientific Corporation received FDA approval for WATCHMAN FLX/FLX Pro indications for patients following catheter ablation for NVAF and added a post-implant drug regimen.
• April 2025: ATRICURE, INC. announced the first use of the AtriClip PRO-Mini LAA Exclusion System for minimally invasive concomitant procedures.
• February 2025: MicroPort Scientific Corporation’s AnchorMan LAA Closure System and access system received EU MDR certification, enabling European commercialization.
• September 2023: Boston Scientific Corporation received FDA approval for WATCHMAN FLX Pro, adding design changes including a thromboresistant surface coating, visualization markers, and an additional size.

REPORT COVERAGE

The report offers a detailed analysis of the global left atrial appendage closure devices market, covering its key segments and the major drivers, restraints, opportunities, challenges, and trends influencing market growth. It also evaluates key industry developments, prevalence/incidence of key diseases, the competitive landscape, market share analysis, and detailed profiles of leading companies operating in the market.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom-Up Approaches

Approach 1: Revenues and Market Share of Major LAA Closure Device Players

• Collection of LAA closure device-attributable revenues from annual reports, SEC filings, investor presentations, earnings releases, and company disclosures of major players such as Boston Scientific, Abbott, AtriCure, LifeTech Scientific, Medtronic, and others.
• Estimation of company market shares based on device revenues, commercial implant volumes, product portfolio, geographic presence, regulatory approvals, and hospital/structural heart center penetration.
• Triangulation of company-level revenues with regional procedure volumes and country-level adoption indicators to derive the global market estimate.

Approach 2: Product-Level Sales and Procedure Volume Analysis

• Identification of major commercial LAA closure systems across transcatheter occlusion, surgical/epicardial exclusion, and dedicated ligation categories.
• Estimation of annual implant volumes, procedure volumes, product mix, and manufacturer-level ASPs across major countries.
• Market value was estimated using commercial device volumes × manufacturer ASP, with adjustments for regional pricing, tender dynamics, product premiumization, and device mix.
• Calculated revenues were reconciled with disclosed manufacturer revenues and commercial implant trends.

Approach 3: Eligible Patient and Procedure Penetration Model

• Assessment of diagnosed atrial fibrillation/NVAF populations, moderate-to-high stroke-risk patients, high-bleeding-risk patients, and patients unsuitable for long-term oral anticoagulation.
• Estimation of the proportion of eligible patients receiving transcatheter LAA occlusion, surgical LAA exclusion, or ligation procedures.
• Eligible procedure volumes were multiplied by device utilization rates and country-specific manufacturer ASPs to estimate country and regional market sizes.

2. Top-Down Approaches

Approach 4: Analysis of Addressable AF Stroke-Prevention Market

• Analysis of the global atrial fibrillation population and identification of patients at elevated thromboembolic risk who are potential candidates for non-pharmacological stroke prevention.
• Estimation of the share eligible for LAA closure based on anticoagulation contraindications, bleeding risk, clinical guidelines, treatment access, and procedural penetration.
• The addressable patient pool was converted into device demand using procedure adoption rates and manufacturer ASPs, and triangulated against bottom-up company and procedure estimates.

3. List of Key Sources

• Boston Scientific, Abbott, AtriCure, Medtronic, LifeTech Scientific, and other companies' annual reports and investor presentations
• SEC filings and earnings releases
• FDA, EU MDR/CE Marking, PMDA, NMPA, CDSCO, and TGA
• ACC, AHA, HRS, SCAI, ESC, EHRA, STS, and EACTS
• NCDR LAAO Registry and other national cardiovascular registries
• CMS and national reimbursement/HTA agencies
• WHO, OECD, Eurostat, and World Bank
• Peer-reviewed clinical studies, randomized trials, real-world evidence, and post-market studies
• Product approvals, label expansions, launches, recalls, and geographical commercialization announcements

4. Primary Interviews

Supply-Side Interviews: 60%

• Key Respondents:
  • LAA closure device manufacturers, distributors, structural heart product managers, sales executives, regional business heads, and procurement specialists
  • Discussions focused on device revenues, unit sales, ASPs, product mix, competitive positioning, geographical penetration, and commercialization trends

Demand-Side Interviews: 40%

• Key Respondents:
  • Interventional cardiologists, electrophysiologists, cardiac surgeons, structural-heart specialists, hospital procurement teams, and cath-lab administrators
  • Discussions focused on procedure volumes, patient selection, device preference, reimbursement, hospital adoption, procedural capacity, and barriers to LAA closure utilization